43.29
-0.38 (-0.87%)
| Penutupan Terdahulu | 43.67 |
| Buka | 43.97 |
| Jumlah Dagangan | 32,870 |
| Purata Dagangan (3B) | 140,932 |
| Modal Pasaran | 405,551,968 |
| Harga / Buku (P/B) | 2.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| EPS Cair (TTM) | -9.42 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.26% |
| Nisbah Semasa (MRQ) | 11.23 |
| Aliran Tunai Operasi (OCF TTM) | -73.69 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.13 M |
| Pulangan Atas Aset (ROA TTM) | -35.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -74.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Korro Bio, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.44% |
| % Dimiliki oleh Institusi | 91.36% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2024 | 368,085 |
| 72 Investment Holdings, Llc | 30 Sep 2024 | 276,831 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 153.00 (Raymond James, 253.43%) | Beli |
| Median | 122.50 (182.98%) | |
| Rendah | 105.00 (RBC Capital, 142.55%) | Beli |
| Purata | 125.75 (190.48%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 62.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Nov 2024 | 115.00 (165.65%) | Beli | 52.31 |
| 13 Nov 2024 | 115.00 (165.65%) | Beli | 55.01 | |
| Jones Trading | 18 Nov 2024 | 130.00 (200.30%) | Beli | 46.63 |
| RBC Capital | 21 Oct 2024 | 105.00 (142.55%) | Beli | 75.86 |
| Raymond James | 21 Oct 2024 | 153.00 (253.43%) | Beli | 75.86 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Nov 2024 | Pengumuman | Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency |
| 21 Nov 2024 | Pengumuman | Korro to Participate in Upcoming Investor Conferences |
| 14 Nov 2024 | Pengumuman | Korro to Present at the Jefferies London Healthcare Conference |
| 12 Nov 2024 | Pengumuman | Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 04 Nov 2024 | Pengumuman | Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board |
| 30 Sep 2024 | Pengumuman | Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |